Hyperpigmentation Disorder Treatment Market is expected to reach US$ 11.78 billion by 2030
Cosmeceuticals Segment, by Treatment Type, is Anticipated to Hold the Largest Share of the Hyperpigmentation Disorder Treatment Market
According to our new research study on "Hyperpigmentation Disorder Treatment Market Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis," the market is expected to grow from US$ 6.67 billion in 2022 to US$ 11.78 billion by 2030; it is estimated to register a CAGR of 7.4% from 2022 to 2030. Rising patient population suffering from skin discoloration disorders is a major factor driving the market growth. However, the high cost of new hyperpigmentation disorder treatment procedures is expected to hamper the hyperpigmentation disorder treatment market growth.
Hyperpigmentation is a common dermatologic condition referring to skin darkening due to excessive melanin production in the epidermis or dermis layer. It is not harmful but can be perceived as a significant cosmetic flaw and becomes a persistent psychological burden for the patient if not addressed in time.
Hyperpigmentation Disorder Treatment Market, by Geography, 2022 (%)
To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00029977
Source: The Insight Partners Analysis
Hyperpigmentation Disorder Treatment Market Driving Factors
Increasing incidences of skin discoloration disorders propel the hyperpigmentation disorder treatment market size. Hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation (PIH), and solar lentigines (age spots) are common dermatological conditions caused in individuals with pigmented skin (Blacks, mixed ancestry, Indians, Hispanics, and African Americans). According to an article published by the Royal Australian College of General Practitioners in December 2021, melasma affects ~1% of the global population. However, people with darker skin types (III-V) are more likely to develop it. The prevalence rate in people of Latin American, Southeast Asian, and South Asian ethnicity can be as high as 40%.
Similarly, PIH is caused by acne and is reported in 45.5–87.2% of patients with acne, according to an article published by the British Journal of Dermatology in February 2023. Hyperpigmentation disorders have a significant impact on the mental and social well-being of the patients, driving consumer demand for skin-bleaching cosmetic products. According to an article published by PubMed Central in August 2021, skin-lightening treatments are widely utilized in countries such as South Korea, Malaysia, and the Philippines to treat dark spots and pigmentation. In Nigeria, over 77% of women use these products regularly, and in India, skin-lightening products account for 61% of the skincare market.
Therefore, as the prevalence of hyperpigmentation disorders continues to rise globally, the demand for skin-lightening agents as a widely accessible treatment option contributes significantly to boost hyperpigmentation disorder treatment market growth.
Emerging Market Trends:
The rising prevalence of hyperpigmentation disorders has led to a surge in the clinical research and development of new innovative products that are safe and efficient for long-term use. With the growing importance of maintaining a healthy lifestyle, cosmeceuticals and cosmetics have become essential to people's daily routines. These new advancements include laser therapies and the utilization of nanotechnology for the formulation of topical treatments. For instance, a study “A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia,” published in the Journal of Drugs in Dermatology (JDD) in May 2023, 43 subjects with mild to severe facial dyschromia were enrolled and randomized to receive either a novel topical product with PATH-3 Technology from Alastin Skincare in Carlsbad, CA, or topical hydroquinone 4% was prescribed to apply twice daily. The study concluded that the hydroquinone 4% group experienced five adverse effects, while no adverse events were reported in the group that used the new topical product with PATH-3 Technology.
Further, market players focused on launching new products with the rising demand for hyperpigmentation treatments. For instance, in March 2023, Candela Corporation received approval from the US Food and Drug Administration (FDA) and Health Canada for its PicoWay laser. The laser technology is designed with photoacoustic energy. It includes four picosecond wavelengths and three beam technologies, with full beam, microbeam, and a fusion beam for treating hyperpigmentation disorders such as café au lait, lentigines, melasma, and Nevus of Ota.
Therefore, emerging technologies are expected to be the hyperpigmentation disorder treatment market trends in the near future.
Hyperpigmentation Disorder Treatment Market Analysis Based on Segmental Evaluation:
By treatment type, the market is segmented into cosmeceutical, chemical peel, cryotherapy, and light or laser therapy, microdermabrasion, and others. The cosmeceutical segment held the largest hyperpigmentation disorder treatment market share in 2022. The microdermabrasion segment is anticipated to register the highest CAGR during 2022–2030.
Based on disease type, the market is segmented into age spots, melasma, post-inflammatory, and others. The melasma segment held the largest hyperpigmentation disorder treatment market share in 2022. The post-inflammatory segment is anticipated to record the fastest CAGR from 2022 to 2030.
Based on end user, the market is segmented into hospitals, dermatology centers, and others. The hospitals segment held the largest market share in 2022. This can be attributed to the availability of better facilities and skilled physicians in hospitals over other surgical centers to perform minimally invasive procedures. Further, the dermatology centers segment is anticipated to register the highest CAGR during the forecast period.
Apart from highlighting factors affecting the market, the hyperpigmentation disorder treatment market report depicts the developments of prominent players. Abbvie Inc. (Allergen, Inc.), Bayer AG, Epipharm AG, Galderma Laboratories, Obagi Cosmeceuticals LLC., Lutronic Corporation, La Pristine, La Roche-Posay, Pierre Fabre Group, and Vivier Pharma USA are among the top players operating in the market. The companies have been implementing various strategies that contribute to their growth and led to various changes in the market. The companies utilize organic strategies (such as product launches, expansion, and product approvals) and inorganic strategies (such as collaborations and partnerships) to stay competitive in the market.
A few initiatives taken by key players operating in the global hyperpigmentation disorder treatment market are listed below:
In January 2023, Allergan Aesthetics, a subsidiary of AbbVie company, launched the SkinMedica Even & Correct Collection. This collection includes advanced brightening and dark spot reduction cream and brightening treatment pads formulated with ultra-concentrated lotus sprout extract, tranexamic acid, and niacinamide.
Similarly, in October 2022, Galderma launched Alastin Skincare A-Luminate Brightening Serum, a novel formulation developed to reduce hyperpigmentation. This serum is a multifaceted blend of peptides, antioxidants, and targeted ingredients and contains ALASTIN's PATH-3 Technology that helps minimize surface pigmentation and protects against future damage.
The scope of the hyperpigmentation disorder treatment market report focuses on North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Spain, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Contact Us
Contact Person: Content Team
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
